Blockchain Registration Transaction Record

Cybin Announces CEO Transition as Company Advances Mental Health Breakthroughs

Cybin announces CEO transition with Eric So taking interim role. Company advances CYB003 for depression and CYB004 for anxiety disorders in late-stage clinical trials.

This leadership change at Cybin matters because the company is developing potentially transformative treatments for mental health conditions that affect millions worldwide. With depression and anxiety disorders representing massive unmet medical needs, Cybin's novel psychedelic-inspired compounds could revolutionize mental healthcare by providing more effective and durable treatment options. The transition comes at a critical juncture as the company approaches commercialization phases for its leading drug candidates, making stable leadership essential for bringing these innovative therapies to patients who have limited effective treatment options currently available.